

CanSinoBIO accelerates overseas growth as vaccine portfolio and mRNA pipeline expand

August 31, 2026 | News

Overseas revenue reached RMB150 million in 1H 2026 as the company expanded vaccine registrations across international markets and advanced new pertussis, pneumococcal and mRNA programmes.



CanSino Biologics reported continued momentum in its international business during the first half of 2026, alongside progress across its marketed vaccines, regulatory-stage products and next-generation pipeline.

The company recorded approximately RMB550 million in revenue for the period, an increase of 43.8% year-on-year, while its net loss attributable to shareholders narrowed significantly.

Overseas revenue reached RMB150 million as CanSinoBIO continued to expand mature products into international markets and develop broader partnership models involving technology collaboration and local industrialisation.

The company said its overseas business is increasingly evolving beyond finished-product exports towards a model in which products, manufacturing processes and technical capabilities are commercialised across international markets.

Registration and commercialisation activities are progressing across Southeast Asia, South America and the Middle East.

Menhycia, CanSinoBIO's quadrivalent meningococcal conjugate vaccine, has received registration approvals in Indonesia and Argentina, with product supply already underway in Indonesia.

The international growth comes as China's vaccine market continues to face pressure from changing demographics and weaker demand in traditional paediatric vaccine segments.

CanSinoBIO said its strategy is therefore increasingly centred on product upgrades, differentiated technologies and expansion into overseas markets.

In China, Menhycia expanded its indicated population in February to include children aged three months to six years.

The company is also expanding market access for iPneucia, its 13-valent pneumococcal conjugate vaccine using CRM197 and tetanus toxoid carrier proteins.

Since its launch in September 2025, iPneucia has become available across nearly 30 provincial-level markets in China.

The company's pertussis vaccine portfolio also continued to advance.

Tripecia, CanSinoBIO's three-component acellular diphtheria, tetanus and pertussis combined vaccine for infants, received New Drug Application approval in April 2026.

The first commercial batches received Certificates for Batch Release of Biological Products in August, with provincial tendering and market access activities now underway.

CanSinoBIO is also developing Td5cp, a tetanus, reduced diphtheria and five-component acellular pertussis vaccine intended for adolescents and adults.

The product has been granted Priority Review status and its New Drug Application has been accepted by China's National Medical Products Administration.

Tetcia, the company's independently developed adsorbed tetanus vaccine, has also received formal approval, further expanding CanSinoBIO's adult immunisation portfolio.

In pneumococcal disease, CanSinoBIO's 24-valent pneumococcal polysaccharide conjugate vaccine entered Phase I/II clinical development in May 2026, with enrolment progressing across different cohorts.

Development is also continuing for its DT3cP-Hib-MCV4 combination vaccine as the company expands towards increasingly multivalent vaccine formats.

Beyond preventive vaccines, CanSinoBIO is building its mRNA technology platform across both infectious disease and therapeutic applications.

The company is conducting early-stage research into mRNA programmes for glioblastoma, rhabdomyosarcoma and cervical cancer, while also exploring in vivo CAR-based therapies.

On 25 August, subsidiary CanSino Shanghai entered into a strategic collaboration with deepGeneAI to develop personalised mRNA therapeutic cancer vaccines.

The partnership will combine CanSinoBIO's mRNA vaccine technology with deepGeneAI's tumour neoantigen discovery and design capabilities.

CanSinoBIO said its broader platform capabilities span viral vector vaccines, synthetic vaccines, protein structure design, virus-like particle assembly, mRNA technologies and formulation and delivery systems.

The company is positioning these platforms as the foundation for future product development and international expansion.

As domestic vaccine demand patterns evolve, CanSinoBIO is increasingly relying on a combination of differentiated products, global market access and technology-driven pipeline development to support longer-term growth.